中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.017 seconds)

    Method, composition and kit for screening ALK or ROS-1 kinase inhibitor
    1.
    发明授权
    Method, composition and kit for screening ALK or ROS-1 kinase inhibitor 有权

    公开(公告)号：US11506654B2

    公开(公告)日：2022-11-22

    申请号：US16409548

    申请日：2019-05-10

    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

    Inventor： Byung Hwa Jung ,  Hyun Beom Lee ,  Naeun Yoon

    IPC: G01N33/50 ,  G01N33/574

    Abstract: A method, a composition and a kit for screening an ALK or ROS-1 kinase inhibitor are disclosed in the present specification. In an aspect, by the method, composition and kit for screening an ALK or ROS-1 kinase inhibitor according to the present disclosure, it is possible to conduct simultaneous quantitative and qualitative analysis and faster screening of a larger number of candidate substances as compared with conventional molecular biological experimental methods and to grasp the overall level of change in a plurality of different metabolites in a cell line by candidate substances of ALK or ROS-1 kinase inhibitor and thus the screening efficiency for drugs which exert an ALK or ROS-1 kinase inhibitory effect is excellent. Consequently, the present disclosure has an advantage of being able to be used in various ways in the development of new drugs which exert an ALK or ROS-1 kinase inhibitory effect.

    Multi-metabolites platform for diagnosis of acute coronary syndrome
    3.
    发明授权
    Multi-metabolites platform for diagnosis of acute coronary syndrome 有权

    公开(公告)号：US10119957B2

    公开(公告)日：2018-11-06

    申请号：US14795163

    申请日：2015-07-09

    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

    Inventor： Byung Hwa Jung ,  Jong Min Choi ,  Hong Seog Seo

    IPC: G01N33/49 ,  G01N33/68

    Abstract: The present disclosure provides a multi-metabolite platform using one or more metabolite selected from a group consisting of tryptophan, homoserine, fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2), fatty acid (22:6), phosphatidylcholine (PC) (34:2), PC (34:3), lysophosphatidylcholine (lysoPC) (16:0), lysoPC (18:0), lysoPC (20:3), lysoPC (20:4), lysoPC (22:6), monoglyceride (18:1/0:0/0:0) and sphingomyelin (d18:2/16:0) as a biomarker, which can diagnose acute coronary syndrome as well as the symptoms occurring prior to the onset of the disease simply and accurately through in-vivo level analysis.

    Diagnostic method of cardiovascular disease
    8.
    发明授权
    Diagnostic method of cardiovascular disease 有权
    心血管疾病诊断方法

    公开(公告)号：US09354222B2

    公开(公告)日：2016-05-31

    申请号：US14185300

    申请日：2014-02-20

    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

    Inventor： Byung Hwa Jung ,  Jong Min Choi

    IPC: G01N33/49 ,  G01N30/72 ,  G01N33/92

    CPC classification number: G01N33/492 ,  G01N30/72 ,  G01N33/92 ,  G01N2800/324 ,  Y10T436/24

    Abstract: Biological metabolites LysoPC (18:0), LysoPC (20:3), fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2) and fatty acid (22:6) according to the present disclosure allow for simple and accurate diagnosis of a cardiovascular disease since their level in the blood of a subject increases or decreases if the subject has a cardiovascular disease such as myocardial infarction or angina. In addition, whereas the existing biomarkers can diagnose only whether myocardial infarction occurs or not, the biological metabolites according to the present disclosure can diagnose not only myocardial infarction but also unstable angina occurring prior to the onset of myocardial infarction stage by stage.

    Abstract translation: 生物代谢物LysoPC（18：0），LysoPC（20：3），脂肪酸（16：1），脂肪酸（18：0），脂肪酸（18：1） （22：6）允许对心血管疾病进行简单和准确的诊断，因为如果受试者患有心血管疾病如心肌梗塞或心绞痛，则他们的受试者的血液中的水平增加或减少。 另外，现有的生物标志物只能诊断心肌梗塞是否发生，根据本发明的生物代谢物不仅可以诊断心肌梗死，还可以诊断心肌梗死发生阶段之前发生的不稳定型心绞痛。

Patent Agency Ranking